European Commission, in 'unprecedented' move, declines to revoke approval of PTC Duchenne drug
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Danielle Brill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HRMY earnings call for the period ending March 31, 2024.
Operator: Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call. At this time all participants are in a listen-only mode.
SRPT earnings call for the period ending December 31, 2023.
REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.43 EPS, expectations were $-1.27. REGENXBIO Inc.